Chronic Ankle InstabilityPhase 1NCT04322409
NMES and Chronic Ankle Instability
A Phase 1 study testing Neuromuscular Electrical Stimulation and Transcutaneous Electrical Nerve Stimulation in people with Chronic Ankle Instability, run by Appalachian State University at 1 site in United States.
Trial summary
Chronic ankle instability is associated with changes in the nervous system that amount to increased difficulty in activating the stabilizing muscles of the ankle. Neuromuscular Electrical Stimulation involves using electricity to activate those muscles in bursts, and is commonly used to improve muscle function in… Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Chronic Ankle Instability
- What is being tested?
- Neuromuscular Electrical Stimulation and Transcutaneous Electrical Nerve Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 26 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2019to 1 Nov 2020
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Subjects will be healthy subjects between the ages of 18-35. The primary inclusion criteria for this study is the presence of chronic ankle instability (CAI). According to guidelines from the International Ankle Consortium, this means subjects will report having a history of one or more ankle sprains (the first >1 year ago), and repeated sensations of giving-way as measured by a score >10 on the Identification of Functional Ankle Instability instrument (IDFAI).
Who cannot join
- History of fracture or surgery to the legs
- Injury to the lower legs within 3 months prior to reporting for testing that resulted in modified physical activity.
- Currently involved in an ankle rehabilitation program.
- Failing to meet standards for the safe practice of transcranial magnetic stimulation and transcranial direct current stimulation (See questionnaire). Briefly, this includes personal or family history of seizure or epilepsy; current medication use that raises risk of seizure; implanted metal, medication devices, etc.; history of brain or heart surgery; and sensitivity of the scalp or skin.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Leon Levine Hall for Health Sciences
Boone, North Carolina, 28608
Alan R Needle, 828-262-4039, needlear@appstate.edu
About this study
Official title: The Role of Neuromuscular Electrical Stimulation (NMES) on Improving Function in Individuals With Chronic Ankle Instability
Chronic ankle instability is associated with changes in the nervous system that amount to increased difficulty in activating the stabilizing muscles of the ankle. Neuromuscular Electrical Stimulation involves using electricity to activate those muscles in bursts, and is commonly used to improve muscle function in those with ACL injury. This study will provide 5 treatments over 2 weeks in patients with Chronic Ankle Instability and determine if Electrical Stimulation can change neural excitability, balance, neuromuscular control, and perceived function in these individuals.
Read the detailed description
Individuals with joint injuries, including ankle sprain and anterior cruciate ligament (ACL) injury have been observed to exhibit changes in central nervous system function that potentially predispose them for further injury (Needle et al. 2017). In ankle sprains, repeated sensations of rolling and giving-way known as chronic ankle instability (CAI) emerges in nearly 50 percent of those with a history of ankle sprain (Holland et al. 2019), with symptoms tied to changes in central nervous system function. As the understanding of these pathologies have expanded, researchers have begun to attempt to identify neuromodulatory interventions capable of addressing injury-induced maladaptive neuroplasticity, thus improving function (Bruce et al. 2020, In Press).
Among those with ACL injury, one of the most common interventions implemented to overcome muscle activation deficits includes neuromuscular electrical stimulation (NMES) (Lepley et al. 2015). This intervention is often used in the initial stages of post-surgical recovery to improve quadriceps function; however, it's use in other populations of joint injury (i.e. ankle sprain) is far more limited. Some previous research has looked at the effects of NMES on acute ankle sprains, as this is the timeframe in which muscle activation deficits would be most evident (Wainwright et al. 2019), but there is very limited evidence in those with CAI. It was potentially thought that activation deficits are less evident and strengthening may overcome these deficits in those with chronic injury; however, new insights have identified additional mechanisms by which NMES may be effective (Lepley et al. 2015). Aside from generating activation of a generally inactive muscle, NMES when performed at high intensities has been described to improve neuromuscular function through disinhibitory mechanisms. That is that increased somatosensation from the electrical stimulation raises the central nervous sytem's awareness of that muscle's activation, yielding decreased inhibition and ultimately increased neural excitability.
Our previous research using cortically-directed interventions demonstrated that improving neural excitability yielded better function in patients with chronic ankle instability (Bruce et al. 2020). This study will follow a similar framework; however, determining if these changes can be induced via a peripheral intervention. These findings have the ability to reframe the current treatment for CAI.
We are pursuing the following 2 specific aims:
- To determine if NMES changes neural excitability (MEP size, H:M ratio, silent period) compared to a placebo treatment in participants with chronic ankle instability. H1: NMES will increase MEP size, H:M ratio, and decrease cortical silent period in individuals with CAI compared to the placebo treatment.
- To determine if changes in neural excitability related to NMES or placebo treatment result in improved function (balance, muscle activation, outcomes) in participants with chronic ankle instability.
H2: Increased neural excitability will yield improved balance (postural stability indices), muscle activation, and patient-reported function.
- Conditions
- Chronic Ankle Instability
- Being tested
- Neuromuscular Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromuscular Electrical StimulationDevice
Also called NMES
5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of "on" time, and 50 seconds off, with 10 cycles being performed each session.
Transcutaneous Electrical Nerve StimulationDevice
Also called TENS
5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
| Study group | Role | What they receive |
|---|---|---|
| NMES | Experimental | The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus. Receives: Device: Neuromuscular Electrical Stimulation |
| TENS | Placebo comparator | The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus Receives: Device: Transcutaneous Electrical Nerve Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tibialis Anterior corticospinal excitability
Motor evoked potential size of tibialis anterior
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Soleus corticospinal excitability
Motor evoked potential size of soleus
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Peroneus Longus corticospinal excitability
Motor evoked potential size of peroneus longus
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Tibialis anterior reflexive excitability
H:M ratio of tibialis anterior
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Soleus reflexive excitability
H:M ratio of soleus
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Peroneus longus reflexive excitability
H:M ratio of peroneus longus
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Secondary outcomes (10)
Dynamic postural stability index
Postural stability indices during a hop-to-stabilization task
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Tibialis Anterior muscle activation
Mean electromyography from the tibialis anterior during a hop-to-stabilization task
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Soleus muscle activation
Mean electromyography from the soleus during a hop-to-stabilization task
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Peroneus Longus muscle activation
Mean electromyography from the peroneus during a hop-to-stabilization task
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Ankle Eversion Strength
Isometric ankle eversion strength
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Side-to-side Hop Test
Time to complete 10 hops over 30 cm lines
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Patient-reported outcomes
Foot \& Ankle ability measure, Disablement in the Physically Active Scale, Tampa Scale for Kinesiophobia
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Foot & Ankle ability measure
Subjects complete FAAM questionnaire
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Disablement in the Physically Active Scale
Subjects complete DPA questionnaire
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Tampa Scale for Kinesiophobia
Subjects complete TSK-11 questionnaire
Measured: Baseline, Week-2 (end of intervention), Week-4 (retention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2020
- Study start1 Nov 2019
- Primary completion30 Jun 2020 (estimated)
- Study completion1 Nov 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Ankle InstabilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2x3 Factorial; 2 groups by 3 time points
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Appalachian State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04322409
- Sponsor's protocol ID
- 20-042
- Status last verified
- Mar 2020
- First submitted
- 7 Jan 2020
- Last updated
- 26 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Needle AR, Tinsley JE, Cash JJ, Koeval BK, Barton JA, Howard JS. The effects of neuromuscular electrical stimulation to the ankle pronators on neural excitability & functional status in patients with chronic ankle instability. Phys Ther Sport. 2023 Mar;60:1-8. doi: 10.1016/j.ptsp.2022.12.001. Epub 2022 Dec 9.
PubMed 36634453
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Neuromuscular Electrical Stimulation (NMES) on Improving Function in Individuals With Chronic Ankle Instability
- ClinicalTrials.gov ID
- NCT04322409
- Acronym / sponsor ID
- 20-042
- Conditions
- Chronic Ankle Instability
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- Appalachian State UniversityUniversity, hospital or other
- Study start
- 1 Nov 2019 (actual)
- Primary completion
- 30 Jun 2020 (estimated)
- Study completion
- 1 Nov 2020 (estimated)
- First posted
- 26 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic ankle instability is associated with changes in the nervous system that amount to increased difficulty in activating the stabilizing muscles of the ankle. Neuromuscular Electrical Stimulation involves using electricity to activate those muscles in bursts, and is commonly used to improve muscle function in those with ACL injury. This study will provide 5 treatments over 2 weeks in patients with Chronic Ankle Instability and determine if Electrical Stimulation can change neural excitability, balance, neuromuscular control, and perceived function in these individuals.
Detailed description
Individuals with joint injuries, including ankle sprain and anterior cruciate ligament (ACL) injury have been observed to exhibit changes in central nervous system function that potentially predispose them for further injury (Needle et al. 2017). In ankle sprains, repeated sensations of rolling and giving-way known as chronic ankle instability (CAI) emerges in nearly 50 percent of those with a history of ankle sprain (Holland et al. 2019), with symptoms tied to changes in central nervous system function. As the understanding of these pathologies have expanded, researchers have begun to attempt to identify neuromodulatory interventions capable of addressing injury-induced maladaptive neuroplasticity, thus improving function (Bruce et al. 2020, In Press).
Among those with ACL injury, one of the most common interventions implemented to overcome muscle activation deficits includes neuromuscular electrical stimulation (NMES) (Lepley et al. 2015). This intervention is often used in the initial stages of post-surgical recovery to improve quadriceps function; however, it's use in other populations of joint injury (i.e. ankle sprain) is far more limited. Some previous research has looked at the effects of NMES on acute ankle sprains, as this is the timeframe in which muscle activation deficits would be most evident (Wainwright et al. 2019), but there is very limited evidence in those with CAI. It was potentially thought that activation deficits are less evident and strengthening may overcome these deficits in those with chronic injury; however, new insights have identified additional mechanisms by which NMES may be effective (Lepley et al. 2015). Aside from generating activation of a generally inactive muscle, NMES when performed at high intensities has been described to improve neuromuscular function through disinhibitory mechanisms. That is that increased somatosensation from the electrical stimulation raises the central nervous sytem's awareness of that muscle's activation, yielding decreased inhibition and ultimately increased neural excitability.
Our previous research using cortically-directed interventions demonstrated that improving neural excitability yielded better function in patients with chronic ankle instability (Bruce et al. 2020). This study will follow a similar framework; however, determining if these changes can be induced via a peripheral intervention. These findings have the ability to reframe the current treatment for CAI.
We are pursuing the following 2 specific aims:
- To determine if NMES changes neural excitability (MEP size, H:M ratio, silent period) compared to a placebo treatment in participants with chronic ankle instability. H1: NMES will increase MEP size, H:M ratio, and decrease cortical silent period in individuals with CAI compared to the placebo treatment.
- To determine if changes in neural excitability related to NMES or placebo treatment result in improved function (balance, muscle activation, outcomes) in participants with chronic ankle instability.
H2: Increased neural excitability will yield improved balance (postural stability indices), muscle activation, and patient-reported function.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- 2x3 Factorial; 2 groups by 3 time points
| Arm | Type | Receives |
|---|---|---|
| NMES | Experimental | Device: Neuromuscular Electrical StimulationThe experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus. |
| TENS | Placebo comparator | Device: Transcutaneous Electrical Nerve StimulationThe placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Subjects will be healthy subjects between the ages of 18-35. The primary inclusion criteria for this study is the presence of chronic ankle instability (CAI). According to guidelines from the International Ankle Consortium, this means subjects will report having a history of one or more ankle sprains (the first >1 year ago), and repeated sensations of giving-way as measured by a score >10 on the Identification of Functional Ankle Instability instrument (IDFAI).
Key exclusion criteria (4 listed)
- History of fracture or surgery to the legs
- Injury to the lower legs within 3 months prior to reporting for testing that resulted in modified physical activity.
- Currently involved in an ankle rehabilitation program.
- Failing to meet standards for the safe practice of transcranial magnetic stimulation and transcranial direct current stimulation (See questionnaire). Briefly, this includes personal or family history of seizure or epilepsy; current medication use that raises risk of seizure; implanted metal, medication devices, etc.; history of brain or heart surgery; and sensitivity of the scalp or skin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromuscular Electrical StimulationAlso: NMES5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of "on" time, and 50 seconds off, with 10 cycles being performed each session. | Device | NMES |
| Transcutaneous Electrical Nerve StimulationAlso: TENS5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold) | Device | TENS |
Primary outcome
Tibialis Anterior corticospinal excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Motor evoked potential size of tibialis anterior
Soleus corticospinal excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Motor evoked potential size of soleus
Peroneus Longus corticospinal excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Motor evoked potential size of peroneus longus
Tibialis anterior reflexive excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
H:M ratio of tibialis anterior
Soleus reflexive excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
H:M ratio of soleus
Peroneus longus reflexive excitability
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
H:M ratio of peroneus longus
10 secondary outcomes
Dynamic postural stability index
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Tibialis Anterior muscle activation
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Soleus muscle activation
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Peroneus Longus muscle activation
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Ankle Eversion Strength
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Side-to-side Hop Test
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Patient-reported outcomes
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Foot & Ankle ability measure
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Disablement in the Physically Active Scale
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Tampa Scale for Kinesiophobia
Time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2020.
- Derived from this study: PubMed 36634453Needle AR, Tinsley JE, Cash JJ, Koeval BK, Barton JA, Howard JS. The effects of neuromuscular electrical stimulation to the ankle pronators on neural excitability & functional status in patients with chronic ankle instability. Phys Ther Sport. 2023 Mar;60:1-8. doi: 10.1016/j.ptsp.2022.12.001. Epub 2022 Dec 9.
- Individual participant dataSharing planned: No
Related trials for Chronic Ankle Instability
Recruiting
The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Amateur Athletes With Chronic Ankle Instability
Ankle Sprain, Ankle Sprain Strain
Recruiting
The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Chronic Ankle Instability
Ankle Sprains, Ankle Sprain Strain
Recruiting
Functional Biomechanical Analysis in Patients Who Underwent Lateral Ankle Ligament Repair With Augmentation
Chronic Lateral Ankle Instability
Not yet recruiting
Collagen Scaffold Bioaugmentation for ATFL Repair in Chronic Ankle Instability
Chronic Ankle Instability, Ankle Sprain
Recruiting
Comparison of the Effects of Hip and Ankle Focused Progressive Exercise Training on Lower Extremity Function in Athletes With Chronic Ankle Instability
Ankle Sprains
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Neuromuscular Electrical Stimulation and Transcutaneous Electrical Nerve Stimulation in people with Chronic Ankle Instability, run by Appalachian State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Alan R Needle, Ph.D. (8282624039, needlear@appstate.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tibialis Anterior corticospinal excitability (time frame: Baseline, Week-2 (end of intervention), Week-4 (retention)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04322409, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2020.